PMID- 37329543
OWN - NLM
STAT- MEDLINE
DCOM- 20230622
LR  - 20230622
IS  - 1165-158X (Electronic)
IS  - 0145-5680 (Linking)
VI  - 69
IP  - 4
DP  - 2023 Apr 30
TI  - Clinical Efficacy of Glucagon-like Peptide-1 Receptor Agonists in Patients with 
      Type 2 Diabetes: A Meta-analysis.
PG  - 86-93
LID - 10.14715/cmb/2023.69.4.13 [doi]
AB  - Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have been approved to treat 
      type 2 diabetes mellitus (T2DM), which have been considered at the same treatment 
      pattern point as basal insulin (BI). Thus, comprehensively comparing these drugs 
      is conducive to informing the treatment decisions. In this context, this work was 
      developed to evaluate the clinical efficacy and safety of GLP-1 RAs by comparing 
      them with basal insulin. GLP-1 RAs were compared with basal insulin in adults 
      with T2DM with inadequate oral anti-hyperglycemic drug control by searching 
      related literature from MEDLINE, EMBASE, CENTRAL, and PubMed databases, which 
      were published from established the datasets to October 2022. Data on hemoglobin 
      A1c, body weight, and blood glucose were extracted and analyzed. The MD values of 
      HbA1C, weight, and fasting blood glucose (FBG) change were -0.02, -1.37, and 
      -1.68, respectively. Meanwhile, the OR of the hypoglycemia ratio was 0.33. In 
      conclusion, GLP-1 RAs exhibited a great effect on blood glucose and weight 
      control and a better effect on FBG control.
FAU - Shi, Lei
AU  - Shi L
AD  - Department of Endocrinology, Zhejiang Hospital, Hangzhou 310013, Zhejiang 
      Province, China. lancai300244@163.com.
FAU - Meng, Shuai
AU  - Meng S
AD  - Department of Endocrinology, Zhejiang Hospital, Hangzhou 310013, Zhejiang 
      Province, China. lancai300244@163.com.
FAU - Ruan, Yuan
AU  - Ruan Y
AD  - Department of Endocrinology, Zhejiang Hospital, Hangzhou 310013, Zhejiang 
      Province, China. lancai300244@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20230430
PL  - France
TA  - Cell Mol Biol (Noisy-le-grand)
JT  - Cellular and molecular biology (Noisy-le-Grand, France)
JID - 9216789
RN  - 0 (Blood Glucose)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulins)
SB  - IM
MH  - Humans
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Glucagon-Like Peptide-1 Receptor/agonists
MH  - *Hypoglycemic Agents/therapeutic use
MH  - Insulins/therapeutic use
MH  - Treatment Outcome
EDAT- 2023/06/17 19:16
MHDA- 2023/06/19 13:08
CRDT- 2023/06/17 14:10
PHST- 2023/02/09 00:00 [received]
PHST- 2023/06/19 13:08 [medline]
PHST- 2023/06/17 19:16 [pubmed]
PHST- 2023/06/17 14:10 [entrez]
AID - 10.14715/cmb/2023.69.4.13 [doi]
PST - epublish
SO  - Cell Mol Biol (Noisy-le-grand). 2023 Apr 30;69(4):86-93. doi: 
      10.14715/cmb/2023.69.4.13.